Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received paclitaxel 175 mg/m^2 IV Q3W and carboplatin area under the curve (AUC) 6 mg/ml/min IV Q3W once at the start of each 3-week treatment cycle for up to 7 cycles. Participants continued receiving treatment beyond 7 cycles at the investigator's discretion.

One-sided p-value based on log-rank test and stratified by ECOG performance status and prior chemotherapy and/or chemoradiation.

Based on Cox regression model with Efron's method for tie handling with treatment as a covariate stratified by ECOG performance status and prior chemotherapy and/or chemoradiation.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received paclitaxel 175 mg/m^2 IV Q3W and carboplatin area under the curve (AUC) 6 mg/ml/min IV Q3W once at the start of each 3-week treatment cycle for up to 7 cycles. Participants continued receiving treatment beyond 7 cycles at the investigator's discretion.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received paclitaxel 175 mg/m^2 IV Q3W and carboplatin area under the curve (AUC) 6 mg/ml/min IV Q3W once at the start of each 3-week treatment cycle for up to 7 cycles. Participants continued receiving treatment beyond 7 cycles at the investigator's discretion.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received paclitaxel 175 mg/m^2 IV Q3W and carboplatin area under the curve (AUC) 6 mg/ml/min IV Q3W once at the start of each 3-week treatment cycle for up to 7 cycles. Participants continued receiving treatment beyond 7 cycles at the investigator's discretion.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received paclitaxel 175 mg/m^2 IV Q3W and carboplatin area under the curve (AUC) 6 mg/ml/min IV Q3W once at the start of each 3-week treatment cycle for up to 7 cycles. Participants continued receiving treatment beyond 7 cycles at the investigator's discretion.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200 mg Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally daily, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received paclitaxel 175 mg/m^2 IV Q3W and carboplatin area under the curve (AUC) 6 mg/ml/min IV Q3W once at the start of each 3-week treatment cycle for up to 7 cycles. Participants continued receiving treatment beyond 7 cycles at the investigator's discretion.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.

Participants received lenvatinib 20 mg orally daily until disease progression or toxicity and pembrolizumab 200 mg intravenous (IV) once at the start of each 3-week treatment cycle (Q3W) for up to 35 cycles (up to ~2 years). Eligible participants who stopped initial course of pembrolizumab plus lenvatinib and achieved Stable Disease (SD) or better but progressed after discontinuation, initiated a second course of pembrolizumab 200mg IV Q3W (for up to 17 cycles [up to ~ 1 year]) with daily lenvatinib 20 mg orally, at investigator's discretion. Treatment with lenvatinib could have been stopped at any time in the first or second course due to toxicity or disease progression.